About Heat Biologics (NASDAQ:HTBX)
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133
Debt
Debt-to-Equity RatioN/A
Current Ratio1.14%
Quick Ratio1.14%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.51 million
Price / Sales4.57
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book0.88
Profitability
EPS (Most Recent Fiscal Year)($7.10)
Net Income$-11,840,000.00
Net Margins-782.32%
Return on Equity-153.27%
Return on Assets-75.49%
Miscellaneous
Employees19
Outstanding Shares5,660,000
Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions
What is Heat Biologics' stock symbol?
Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."
When did Heat Biologics' stock split? How did Heat Biologics' stock split work?
Heat Biologics's stock reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.
How were Heat Biologics' earnings last quarter?
Heat Biologics (NASDAQ:HTBX) announced its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.30. The biopharmaceutical company earned $0.47 million during the quarter, compared to the consensus estimate of $0.50 million. Heat Biologics had a negative return on equity of 153.27% and a negative net margin of 782.32%. View Heat Biologics' Earnings History.
When is Heat Biologics' next earnings date?
What price target have analysts set for HTBX?
2 Wall Street analysts have issued 1 year price targets for Heat Biologics' shares. Their forecasts range from $22.50 to $22.50. On average, they expect Heat Biologics' share price to reach $22.50 in the next year. View Analyst Ratings for Heat Biologics.
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include OHR Pharmaceutical (OHRP), Onconova Therapeutics (ONTX), RXi Pharmaceuticals (RXII), Acura Pharmaceuticals (ACUR), EpiCept (IMNP), Dare Bioscience (DARE), Auris Medical (EARS), Argos Therapeutics (ARGS), EyeGate Pharma (EYEG), Anthera Pharmaceuticals (ANTH), Bioblast Pharma (ORPN), Apricus Biosciences (APRI), Cotinga Pharmaceuticals (COTQF), Orexigen Therapeutics (OREX), Rosetta Genomics (ROSG), Affymax (AFFY), TetraLogic (TLOG) and Patheon (PTHN).
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the folowing people:
- Mr. Jeffrey Alan Wolf J.D., Founder, Chairman, Chief Exec. Officer, Pres and Treasurer (Age 55)
- Ms. Ann A. Rosar M.B.A., VP of Fin. & Corp. Sec. (Age 66)
- Dr. Jeff T. Hutchins Ph.D., Chief Scientific Officer (Age 59)
- Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
- Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor
Has Heat Biologics been receiving favorable news coverage?
News coverage about HTBX stock has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heat Biologics earned a news impact score of 0.09 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Heat Biologics?
Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heat Biologics' stock price today?
One share of HTBX stock can currently be purchased for approximately $1.22.
How big of a company is Heat Biologics?
Heat Biologics has a market capitalization of $6.99 million and generates $1.51 million in revenue each year. The biopharmaceutical company earns $-11,840,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Heat Biologics employs 19 workers across the globe.
How can I contact Heat Biologics?
Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]
MarketBeat Community Rating for Heat Biologics (HTBX)
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Heat Biologics (NASDAQ:HTBX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Heat Biologics in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 1,744.26%. The high price target for HTBX is $22.50 and the low price target for HTBX is $22.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.50 | $22.50 | $22.50 | $21.25 |
| Price Target Upside: | 1,744.26% upside | 320.56% upside | 320.56% upside | 297.20% upside |
Heat Biologics (NASDAQ:HTBX) Consensus Price Target History
Heat Biologics (NASDAQ:HTBX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Heat Biologics (NASDAQ:HTBX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Heat Biologics (NASDAQ HTBX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 65.44%
Heat Biologics (NASDAQ HTBX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/23/2016 | Michael Kharitonov | Director | Buy | 900,000 | $0.75 | $675,000.00 | 949,960 |  |
| 5/19/2014 | Jeffrey Alan Wolf | CEO | Buy | 2,500 | $4.13 | $10,325.00 | | |
| 5/16/2014 | Paul Belsky | Director | Buy | 2,500 | $4.11 | $10,275.00 | | |
(Data available from 1/1/2013 forward)
Heat Biologics (NASDAQ HTBX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Heat Biologics (HTBX) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 19 at 10:12 PM |
| ValuEngine Downgrades Heat Biologics (HTBX) to Strong Sell
www.americanbankingnews.com - April 18 at 4:44 PM |
 | Heat Biologics, Inc.: Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
www.finanznachrichten.de - April 18 at 9:20 AM |
 | Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
finance.yahoo.com - April 18 at 9:20 AM |
| Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?
finance.yahoo.com - April 10 at 4:37 PM |
| Heat Biologics (HTBX) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 26 at 5:58 PM |
 | Heat Biologics (HTBX) Reports Positive Data from Phase 2 Trial Evaluating HS-410 (Vesigenurtacel-L) in Combination with Standard of Care BCG
www.streetinsider.com - March 26 at 9:42 AM |
| Heat Biologics, Inc.: Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
www.finanznachrichten.de - March 26 at 9:42 AM |
| Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
finance.yahoo.com - March 26 at 9:42 AM |
| Heat Biologics (HTBX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 25 at 5:22 PM |
| Heat Biologics (HTBX) vs. Mateon Therapeutics (MATN) Financial Analysis
www.americanbankingnews.com - March 24 at 5:08 AM |
| On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise
finance.yahoo.com - March 20 at 4:28 PM |
| Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
finance.yahoo.com - March 19 at 9:29 AM |
| Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
finance.yahoo.com - March 14 at 5:53 PM |
| Contrasting bluebird bio (BLUE) & Heat Biologics (HTBX)
www.americanbankingnews.com - March 14 at 3:07 PM |
| Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam
finance.yahoo.com - March 13 at 9:36 AM |
| Heat Biologics Adopts Stockholder Rights Plan
finance.yahoo.com - March 12 at 11:16 AM |
| Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 9 at 9:48 AM |
| Heat Biologics Reports Fiscal Year 2017 Financial Results
finance.yahoo.com - March 2 at 5:13 PM |
| Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - February 28 at 9:12 AM |
| UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study
finance.yahoo.com - February 26 at 9:12 AM |
| Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer
finance.yahoo.com - February 20 at 5:01 PM |
| Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond
finance.yahoo.com - February 15 at 4:41 PM |
| Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York
finance.yahoo.com - February 7 at 9:19 AM |
| Critical Review: Clearside Biomedical (CLSD) & Heat Biologics (HTBX)
www.americanbankingnews.com - February 5 at 11:16 AM |
| Today’s Research Reports on Trending Tickers: Heat Biologics and ImmunoGen
finance.yahoo.com - February 1 at 9:21 AM |
| Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study
finance.yahoo.com - January 30 at 9:42 AM |
| Heat latest Triangle biopharma to execute reverse stock split
finance.yahoo.com - January 22 at 5:57 PM |
| Zacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM |
| Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?
finance.yahoo.com - January 2 at 8:59 PM |
| Heat Biologics, Inc. (HTBX) Short Interest Down 41.6% in November
www.americanbankingnews.com - December 16 at 3:42 AM |
| ETFs with exposure to Heat Biologics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:38 PM |
| Heat Biologics (HTBX) Granted FDA Guidance at Type C Meeting for HS-110 Clinical Trial - StreetInsider.com
www.streetinsider.com - December 8 at 11:37 AM |
| Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer
finance.yahoo.com - December 7 at 11:52 AM |
| Zacks: Analysts Set $8.42 Price Target for Heat Biologics, Inc. (HTBX)
www.americanbankingnews.com - December 5 at 11:30 AM |
| ETFs with exposure to Heat Biologics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:38 PM |
| Want To Invest In Heat Biologics Inc (HTBX)? Here’s How It Performed Lately
finance.yahoo.com - November 30 at 12:05 PM |
| Heat Biologics, Inc. :HTBX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 11:24 AM |
| Heat Biologics (HTBX) Terminates Rights Offering
www.streetinsider.com - November 23 at 4:50 PM |
| Heat Biologics (HTBX) Terminates Rights Offering - StreetInsider.com
www.streetinsider.com - November 22 at 8:58 PM |
| Heat Biologics (HTBX) Prices 5.8M Common Stock Offering at $0.43/Share
www.streetinsider.com - November 17 at 11:13 PM |
| Heat Biologics Prices 5,813,950 Shares for Common Stock Offering
finance.yahoo.com - November 17 at 6:08 PM |
| Here’s What’s Behind Heat Biologics Inc (HTBX) Drop Today
finance.yahoo.com - November 17 at 6:08 PM |
| After-Hours Stock Movers 11/16: (SCVL) (SPLK) (ROST) Higher; (HTBX) (WSM) (VBLT) Lower (more...) - StreetInsider.com
www.streetinsider.com - November 17 at 8:01 AM |
| Heat Biologics (HTBX) Announces Proposed Common Share Offering - StreetInsider.com
www.streetinsider.com - November 17 at 8:01 AM |
| Heat Biologics (HTBX) Announces Proposed Common Share Offering
www.streetinsider.com - November 16 at 5:50 PM |
| Heat Biologics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 16 at 5:50 PM |
| Is It Time To Buy Heat Biologics Inc (HTBX)?
finance.yahoo.com - November 14 at 8:06 PM |
| Heat Biologics, Inc. (HTBX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 14 at 7:18 AM |
| Heat Biologics Reports Third-quarter 2017 Results and Corporate Update
finance.yahoo.com - November 13 at 8:56 AM |
Heat Biologics (NASDAQ:HTBX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Heat Biologics (NASDAQ:HTBX) Income Statement, Balance Sheet and Cash Flow Statement
Heat Biologics (NASDAQ HTBX) Stock Chart for Friday, April, 20, 2018
Loading chart…
